CN114767778A - Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis - Google Patents
Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis Download PDFInfo
- Publication number
- CN114767778A CN114767778A CN202210293941.3A CN202210293941A CN114767778A CN 114767778 A CN114767778 A CN 114767778A CN 202210293941 A CN202210293941 A CN 202210293941A CN 114767778 A CN114767778 A CN 114767778A
- Authority
- CN
- China
- Prior art keywords
- beta
- hosta plantaginea
- kaempferol
- plantaginea flower
- hosta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001482471 Hosta plantaginea Species 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000016150 acute pharyngitis Diseases 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000725 suspension Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000003480 eluent Substances 0.000 claims abstract description 10
- 239000000287 crude extract Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000007865 diluting Methods 0.000 claims abstract description 4
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000011068 loading method Methods 0.000 claims abstract description 4
- 238000010992 reflux Methods 0.000 claims abstract description 4
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 241000628997 Flos Species 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- XFFQVRFGLSBFON-UHFFFAOYSA-N 5alpha,12-dihydroxy-6(14)-dehydro-5,6-dihydrocaryophyllen-7-one Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-UHFFFAOYSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 241001607869 Plantagineae Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 30
- 241000700159 Rattus Species 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 10
- 210000003800 pharynx Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 6
- SHZGCJCMOBCMKK-HGVZOGFYSA-N alpha-L-rhamnopyranose Chemical compound C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-HGVZOGFYSA-N 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- LKZDFKLGDGSGEO-UJECXLDQSA-N kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O[C@H](CO)[C@@H](O)[C@@H]1O LKZDFKLGDGSGEO-UJECXLDQSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- LKZDFKLGDGSGEO-UHFFFAOYSA-N 2',8-Di-Me ether,7-O-beta-D-glucuronoside-2',5,7,8-Tetrahydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)C(O)C1O LKZDFKLGDGSGEO-UHFFFAOYSA-N 0.000 description 2
- MBFNAZBJKVFNKZ-OJMLKILZSA-N 3-[(2s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-7-[(2s,4s,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1C(O)[C@H](O)C(CO)O[C@H]1OC1[C@H](OC=2C(C3=C(O)C=C(O[C@H]4C([C@@H](O)[C@H](O)C(CO)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)[C@@H](O)C1O MBFNAZBJKVFNKZ-OJMLKILZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- MBFNAZBJKVFNKZ-UHFFFAOYSA-N kaempferol-3-sophoroside-7-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(OC4C(C(O)C(O)C(CO)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)C(O)C1O MBFNAZBJKVFNKZ-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000720945 Hosta Species 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940041677 topical spray Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a hosta plantaginea flower extract in preparation of a medicine and a health-care food for treating acute pharyngitis. Which comprises the following steps: mixing dried hosta plantaginea flower medicinal material with 70% ethanol water solution, heating and refluxing at 100 ℃ for extraction for 2 hours; carrying out rotary evaporation and concentration on the obtained filtrate at the temperature of 60 ℃ in a water bath to obtain a hosta plantaginea flower crude extract suspension; diluting the obtained hosta plantaginea flower crude extract suspension with water with the same volume, loading the suspension onto a D101 type macroporous adsorption resin column, eluting with pure water, discarding a pure water eluent, eluting with a 40% +/-10% ethanol water solution, eluting a fraction, concentrating under reduced pressure to recover an ethanol solvent, and freeze-drying to obtain the hosta plantaginea flower extract. Animal experiments prove that the hosta plantaginea flower extract provided by the invention has a treatment effect on pharyngitis model animals, and can be used for preparing anti-pharyngitis medicines or health-care foods.
Description
Technical Field
The invention relates to a preparation method of a hosta plantaginea flower extract and application of the hosta plantaginea flower extract in preparation of medicines and health-care foods for treating pharyngitis, and belongs to the field of medicines.
Background
Pharyngitis is nonspecific inflammation of pharynx, is a general name of inflammation caused by infection of pharynx by various microorganisms, can exist alone, can coexist with rhinitis, tonsillitis and laryngitis, or is a prodromal symptom of certain diseases. It can be divided into acute pharyngitis and chronic pharyngitis. Acute pharyngitis is an acute inflammation of the mucous membrane and the tissue under the mucous membrane of the pharynx, and is easily developed in adults by the exchange between autumn, winter and spring. It is mainly manifested as dry, burning, painful throat, obvious pain in swallowing, congestion and swelling of throat.
Flos Hostae Plantagineae is dried flower of Hosta plantaginea of Hosta of Liliaceae, also called flos Neisseria, flos et Gemma Agrimoniae, etc. The hosta plantaginea flower is sweet in nature and cool in taste, has the functions of clearing heat, detoxifying, relieving cough and relieving sore throat, is mainly used for treating lung heat, sore throat, hoarseness, chest pain and toxic heat, and is one of heat-clearing and fire-purging herbs commonly used in Mongolian medicine clinic. The Mongolian medicine Hosta plantaginea Shiwuwei pill for clearing heat from throat, also known as fifteen ingredient white flower and gentian powder, is recorded in the prescription from Gao Yao, and has excellent treatment effects on acute and chronic pharyngitis, sore throat, dry mouth and throat and tonsillitis in clinical application. However, no report on the research on the single treatment of pharyngitis by hosta plantaginea flower is found so far. At present, the medicines taking the hosta plantaginea flowers as the main raw materials are rare in the market, and the hosta plantaginea flowers are developed into medicines or health-care foods with certain curative effects of treating pharyngitis as new products, so that the hosta plantaginea flowers have very wide market prospects and economic benefits.
Disclosure of Invention
In order to fill the market vacancy, the invention aims to provide the application of the hosta plantaginea flower extract in preparing medicines and health-care foods for treating acute pharyngitis.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: the application of hosta plantaginea flower extract in preparing medicine and health food for treating acute pharyngitis is disclosed.
Further, the hosta plantaginea flower extract is 40% +/-10% ethanol water elution fraction of a hosta plantaginea flower 70% ethanol extract adsorbed by macroporous adsorption resin.
Further, the preparation method of the hosta plantaginea flower extract comprises the following steps:
1) mixing a dried hosta plantaginea medicinal material with 70% ethanol aqueous solution according to the material-liquid ratio of 1g:10mL, heating and refluxing at 100 ℃ for 2 hours, filtering, collecting filtrate, repeatedly extracting the residual medicine dregs with 70% ethanol aqueous solution twice, filtering, and collecting filtrate;
2) mixing the filtrates obtained in the step 1) for three times, and performing rotary evaporation and concentration at the temperature of 60 ℃ to recover an ethanol solution to obtain a hosta plantaginea flower crude extract suspension;
3) diluting the hosta plantaginea flower crude extract suspension obtained in the step 2) with water in the same volume, loading the suspension onto a D101 type macroporous adsorption resin column, eluting with water with the volume being 20 times that of the column, discarding the eluent, eluting with 40% +/-10% ethanol aqueous solution, and collecting the eluent;
4) concentrating the eluent obtained in the step 3) under reduced pressure, recovering the solvent, and freeze-drying to obtain the target product hosta plantaginea flower extract.
Further, the hosta plantaginea flower extract contains total flavonoids, and comprises compounds with a structural general formula shown in the formula (I):
wherein,
compound 1: r is1＝β-D-Glc，R2＝β-D-Glc2-β-D-Glc，R3H; kaempferol-3-O-sophoroside-7-O- β -D-glucopyranoside.
Compound 2: r is1＝β-D-Glc，R2＝β-D-Glc4-[α-L–Rha6]-β-D-Glc，R3H; kaempferol-3-O-beta-D-glucopyranosyl- (1 → 4) -alpha-L-rhamnosyl- (1 → 6) -beta-D-glucopyranoside-7-O-beta-D-glucopyranoside.
Compound 3: r1＝β-D-Glc，R2＝β-D-Glc，R3H; kaempferol-3, 7-di-O-beta-D-glucopyranoside.
Compound 4: r1＝β-D-Glc，R2＝β-D-Glc6-α-L-Rha，R3β -D-Glc; kaempferol-3-O-rutinoside-7, 4' -di-O-beta-D-glucopyranoside.
Compound 5: r is1＝β-D-Glc，R2＝β-D-Glc6-α-L-Rha，R3H; kaempferol-3-O-rutinoside-7-O-beta-D-glucopyranoside.
Compound 6: r1＝β-D-Glc，R2＝β-D-Glc3-[α-L–Rha6]-β-D-Glc，R3H; Kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl-pyranosyl- (1 → 6) -beta-D-galactopyranoside-7-O-beta-D-glucopyranoside.
Compound 7: r1＝H，R2＝β-D-Glc2-β-D-Glc，R3H; kaempferol-3-O-sophoroside.
Compound 8: r is1＝H，R2＝β-D-Glc3-[α-L–Rha6]-β-D-Glc，R3H; kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl pyranosyl- (1 → 6) -beta-D-galactopyranoside.
Compound 9: r is1＝H，R2＝β-D-Glc6-α-L-Rha，R3H; kaempferol-7-O-rutinoside.
Further, the hosta plantaginea flower extract is mixed with pharmaceutic adjuvants to be prepared into powder, liquid preparations, tablets, pills, microcapsules, capsules and granules.
The beneficial effects of the invention are: the hosta plantaginea flower extract provided by the invention has a good curative effect on pharyngitis, so that the hosta plantaginea flower extract can be applied to medicines and health-care foods for treating pharyngitis. The natural product extracted from the hosta plantaginea flower has small toxic and side effects on human bodies, and is safe and reliable.
Drawings
FIG. 1 is the level of TNF-. alpha.concentration in serum of rats of each group (x. + -. s).
FIG. 2 is the concentration level (x. + -.s) of IL-6 in the serum of rats of each group.
FIG. 3 is the level of IL-1. beta. concentration (x. + -. s) in serum of rats of each group.
FIG. 4 is a pathological section of pharyngeal mucosa and its lower tissue in each group.
Detailed Description
The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitation of the present invention.
Example 1
Preparation of hosta plantaginea flower extract
1. According to the material-liquid ratio of 1g to 10mL, putting a dried hosta plantaginea medicinal material and 70% ethanol aqueous solution into a round-bottom glass flask, heating and refluxing for extraction for 2 hours at 100 ℃, filtering, collecting filtrate, repeatedly extracting the residual medicine dregs twice with 70% ethanol aqueous solution, filtering, and collecting filtrate.
2. And (2) combining the three filtrates obtained in the step (1), and performing rotary evaporation and concentration on the mixed filtrate at the temperature of 60 ℃ to recover an ethanol solution to obtain a hosta plantaginea flower crude extract suspension.
3. Diluting the hosta plantaginea flower crude extract suspension obtained in the step 2 with water in the same volume, loading the suspension onto a D101 type macroporous adsorption resin column, eluting with water with the volume being 20 times that of the column, discarding the eluent, eluting with 40% +/-10% ethanol aqueous solution, and collecting the eluent;
4. and (4) concentrating the eluent obtained in the step (3) under reduced pressure to recover the solvent, and freeze-drying to obtain a product, namely the hosta plantaginea flower extract.
(II) detection
The total flavone content in the hosta plantaginea flower extract prepared by the method is 83.2 percent by using a rutin standard substance as a reference substance and measuring by using an ultraviolet spectrophotometry, and the main components in the extract comprise compounds with a structural general formula shown in (I):
wherein,
compound 1: r1＝β-D-Glc，R2＝β-D-Glc2-β-D-Glc，R3H; kaempferol-3-O-sophoroside-7-O-beta-D-glucopyranoside.
Compound 2: r is1＝β-D-Glc，R2＝β-D-Glc4-[α-L–Rha6]-β-D-Glc，R3H; kaempferol-3-O-beta-D-glucopyranosyl- (1 → 4) -alpha-L-rhamnosyl- (1 → 6) -beta-D-glucopyranoside-7-O-beta-D-glucopyranoside.
Compound 3: r1＝β-D-Glc，R2＝β-D-Glc，R3H; kaempferol-3, 7-di-O-beta-D-glucopyranoside.
Compound 4: r1＝β-D-Glc，R2＝β-D-Glc6-α-L-Rha，R3β -D-Glc; kaempferol-3-O-rutinoside-7, 4' -di-O-beta-D-glucopyranoside.
Compound 5: r is1＝β-D-Glc，R2＝β-D-Glc6-α-L-Rha，R3H; kaempferol-3-O-rutinoside-7-O-beta-D-glucopyranoside.
Compound 6: r is1＝β-D-Glc，R2＝β-D-Glc3-[α-L–Rha6]-β-D-Glc，R3H; kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl-pyranosyl- (1 → 6) -beta-D-galactopyranoside-7-O-beta-D-glucopyranoside.
Compound 7: r is1＝H，R2＝β-D-Glc2-β-D-Glc，R3H; kaempferol-3-O-sophoroside.
Compound 8: r1＝H，R2＝β-D-Glc3-[α-L–Rha6]-β-D-Glc，R3H; kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl pyranosyl- (1 → 6) -beta-D-galactopyranoside.
Compound 9: r is1＝H，R2＝β-D-Glc6-α-L-Rha，R3H; kaempferol-7-O-rutinoside.
Example 2 evaluation of therapeutic Effect of Hosta plantaginea flower extract on pharyngitis model rats
(I) test materials
Animals: SD rats, 240 + -10 g, plain grade, male, supplied by Liaoning Biotechnology GmbH.
Model: ammonia-induced pharyngitis rat model. Ammonia water is an alkaline irritant, and topical spray can irritate pharyngeal mucosa to cause it to become hyperemic and edematous, and repeated irritation can gradually transform the mucosa into inflammation.
Test drugs: aspirin, hosta plantaginea flower extract prepared in example 1.
The preparation method comprises the following steps: the extract part takes the extractum as a raw material and is diluted to the required concentration by taking water as a solvent.
(II) Experimental method
Model establishment: 50 male rats with the SD strain clean grade are selected, the weight of the male rats is 240 +/-10 g, the male rats are randomly divided into 5 groups, and each group comprises 10 male rats, namely a blank control group, a pharyngitis model group, a natural restoration group, an aspirin group and a hosta plantaginea flower extract group. Spraying 15% ammonia water into pharynx of rats except for the blank control group with 1mL each time for 3 times per day for 4 consecutive days by using a larynx sprayer, and establishing an acute pharyngitis model, and spraying equivalent distilled water into pharynx of rats in the blank control group for 3 times per day for 4 consecutive days.
The administration scheme is as follows: after modeling is completed, the animals of the pharyngitis model group dissect and take pharyngeal mucosa tissues. On day 5, the rats in the other groups were gazed with the corresponding drugs at the prescribed doses 1 time a day for 4 consecutive days. The administered doses are shown in table 1.
TABLE 1 dosage administration
The calculation formula of the 4-day administration dose is as follows:
4 (days of administration). times.10 (number of rats). times.0.20 kg (average weight of rats). times. X g/kg
(dose) 14g (total dose)
X＝1.75g/kg
The gavage amount of each rat was 2ml per day.
And (4) observation indexes are as follows: from the 2 nd day of molding, animals were observed daily for drinking water, diet, activity and pharyngeal condition, including mucosal shape, color, etc., and weighed periodically. Animals were sacrificed on day 11 and pharyngeal mucosa and tissues beneath it were sectioned for pathological observation.
(III) results and conclusions
1. Characterization observations: from the 2 nd day of model building, most animals gradually scratch the mouth, frequently drink water, lose appetite, lose weight, and have symptoms of congestion, swelling and the like at the pharynx, the mucous membrane is bright red, and the symptoms are more obvious at the 3 rd day of model building. The blank control did not see above.
2. Influence of hosta plantaginea flower extract on TNF-alpha, IL-6 and IL-1 beta levels in rat serum
Taking blood from retrobulbar venous plexus, centrifuging at 2500r/min for 20 min, taking serum, freezing at-20 deg.C, and thawing at room temperature. The assay was performed as described in the Shanghai enzyme-linked product.
FIG. 1 shows the TNF-. alpha.concentration levels (x. + -. s) in rat serum. As can be seen from FIG. 1, the TNF-alpha inflammatory factor level of the rats in the pharyngitis model group is obviously improved compared with that of the rats in the blank control group (P < 0.001); the natural recovery group is only slightly reduced compared with the pharyngitis model group; the levels of inflammatory factors of the aspirin group and the hosta plantaginea flower extract group are obviously reduced (P is less than 0.01) compared with the levels of the inflammatory factors of a natural recovery group;
FIG. 2 shows the IL-6 concentration levels (x. + -.s) in rat serum. As can be seen from FIG. 2, the IL-6 inflammatory factor level of the rats in the pharyngitis model group is obviously improved compared with that of the rats in the blank control group (P < 0.001); the natural recovery group is only slightly reduced compared with the pharyngitis model group; the levels of inflammatory factors of the aspirin group and the hosta plantaginea flower extract group are obviously reduced (P is less than 0.01) compared with the levels of the inflammatory factors of a natural recovery group;
FIG. 3 shows IL-1. beta. concentration levels (x. + -. s) in rat serum. As can be seen from FIG. 4, the IL-1 beta inflammatory factor level of the rats in the pharyngitis model group is obviously improved compared with that of the rats in the blank control group (P < 0.001); the natural recovery group is only slightly reduced compared with the pharyngitis model group; the levels of inflammatory factors of the aspirin group and the hosta plantaginea flower extract group are obviously reduced (P is less than 0.001) compared with the levels of the inflammatory factors of the natural recovery group;
in conclusion, compared with natural restoration, the hosta plantaginea flower extract prepared by the invention can effectively improve the level of inflammatory factors after molding.
3. Pathological analysis of pharyngeal mucosa and lower tissues of rats in each group
FIG. 4 is a sectional view of pharyngeal mucosa and lower tissues of the Hosta plantaginea flower extract group, the blank control group, the pharyngitis model group, the natural restoration group and the aspirin group.
The mucosal layer, submucosal layer and adventitia layer of the tissues of the blank control group are clearly visible, the epithelial tissues of the mucosal layer are incomplete and partially shed, no obvious inflammatory reaction is seen in the tissues, and the submucosal layer is locally slightly edematous and is accompanied by infiltration of a small amount of inflammatory cells (including granulocytes and lymphocytes) (see fig. 4A).
Compared with the blank control group, the visible horned layer of the tissue epidermal layer of the pharyngitis model group falls off in a large range; extensive edema of the dermis, loose connective tissue, and associated with more infiltration of inflammatory cells, including lymphocytes and mast cells; a small range of bleeding was seen in many sites of the dermis with more neutrophil infiltration (see fig. 4B).
The pharyngeal tissue mucous layer epithelium of the natural recovery group can be seen to be exfoliated in a large range; extensive edema of the submucosa and lamina propria, loose connective tissue, and increased infiltration of inflammatory cells (including granulocytes and lymphocytes) were observed (see fig. 4C).
The tissue mucosa epithelium of the aspirin group has uneven thickness, local papillary shape and local hyperplasia; a small amount of inflammatory cell infiltration into the mucosal layer (see figure 4D).
The hosta plantaginea flower extract group had normal tissue structure, the mucosal layer was clearly visible, a small amount of mast cells were seen scattered in the submucosa layer, and the connective tissue was loose (see fig. 4E).
5. The pharyngitis degree rating scores of the rats in each group are shown in Table 2.
The sacrifice was made after 48 hours except for the model group, and the results obtained by the sacrifice made 11 days after the administration were all obtained in the remaining administration groups.
TABLE 2 pharyngitis degree rating score
The test results show that the hosta plantaginea flower extract prepared by the invention has a treatment effect on pharyngitis model animals through animal experiments.
The foregoing shows and describes the general principles, principal features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the foregoing description only for the purpose of illustrating the principles of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims, specification, and equivalents thereof.
Claims (6)
1. The application of the hosta plantaginea flower extract in preparing the medicines and health-care foods for treating the acute pharyngitis is realized by using the hosta plantaginea flower extract singly or together with other medicines.
2. Use according to claim 1, characterized in that: the hosta plantaginea flower extract is 40% +/-10% ethanol water elution fraction of a hosta plantaginea flower 70% ethanol extract adsorbed by macroporous adsorption resin.
3. Use according to claim 2, characterized in that: the preparation method of the hosta plantaginea flower extract comprises the following steps:
1) mixing a dried hosta plantaginea medicinal material with 70% ethanol aqueous solution according to the material-liquid ratio of 1g to 10mL, heating and refluxing at 100 ℃ for 2 hours, filtering, collecting filtrate, repeatedly extracting the residual medicine dregs with 70% ethanol aqueous solution twice, filtering, and collecting filtrate;
2) mixing the filtrates obtained in the step 1) for three times, performing rotary evaporation concentration at the temperature of 60 ℃ in a water bath, and recovering an ethanol solvent to obtain a hosta plantaginea flower crude extract suspension;
3) diluting the hosta plantaginea flower crude extract suspension obtained in the step 2) with water in the same volume, loading the suspension onto a D101 type macroporous adsorption resin column, eluting with water with the volume 20 times that of the column, discarding the eluent, eluting with 40 +/-10% ethanol water solution, and collecting the eluent;
4) concentrating the eluent obtained in the step 3) under reduced pressure to recover the solvent, and freeze-drying to obtain the target product hosta plantaginea flower extract.
4. Use according to claim 1, characterized in that: the hosta plantaginea flower extract contains total flavonoids.
5. Use according to claim 4, characterized in that: the total flavonoids comprise: kaempferol-3-O-sophorose-7-O-beta-D-glucopyranoside, kaempferol-3-O-beta-D-glucopyranosyl- (1 → 4) -alpha-L-rhamnosyl- (1 → 6) -beta-D-glucopyranoside-7-O-beta-D-glucopyranoside, kaempferol-3, 7-di-O-beta-D-glucopyranoside, kaempferol-3-O-rutinoside-7, 4' -di-O-beta-D-glucopyranoside, kaempferol-3-O-rutinoside-7-O-beta-D-glucopyranoside, kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl- (1 → 6) -beta-D-galactopyranoside-7-O-beta-D-glucopyranoside, kaempferol-3-O-sophorose glycoside, kaempferol-3-O-beta-D-glucopyranosyl- (1 → 3) -alpha-L-rhamnosyl- (1 → 6) -beta-D-galactopyranoside, kaempferol-7-O-rutinoside.
6. Use according to claim 1, characterized in that: mixing flos Hostae Plantagineae extract with medicinal adjuvants, and making into powder, liquid, tablet, pill, microcapsule, capsule and granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210293941.3A CN114767778A (en) | 2022-03-24 | 2022-03-24 | Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210293941.3A CN114767778A (en) | 2022-03-24 | 2022-03-24 | Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114767778A true CN114767778A (en) | 2022-07-22 |
Family
ID=82425423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210293941.3A Pending CN114767778A (en) | 2022-03-24 | 2022-03-24 | Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114767778A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951980A (en) * | 2016-10-14 | 2018-04-24 | 四川英路维特医药科技有限公司 | The purposes of fragrant plantain lily flower and its extract in the medicine or health food for preparing treatment chronic prostatitis |
-
2022
- 2022-03-24 CN CN202210293941.3A patent/CN114767778A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951980A (en) * | 2016-10-14 | 2018-04-24 | 四川英路维特医药科技有限公司 | The purposes of fragrant plantain lily flower and its extract in the medicine or health food for preparing treatment chronic prostatitis |
Non-Patent Citations (2)
| Title |
|---|
| 冯婧;胡林峰;唐雨;: "玉簪花的化学成分与药理作用研究进展" * |
| 武毛毛;李春燕;李凤英;薛淑媛;石松利;薛培凤;: "蒙药玉簪花对急性咽炎模型大鼠的治疗作用及对细胞因子的影响" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101040950B (en) | Method of preparing compound Houttuynia cordata dropping pills | |
| CN106474267A (en) | Composition with pharynx-clearing and throat-smoothing action and its preparation method and application | |
| KR20040032920A (en) | Fermentation product of cyptoporus volvatus and its preparation method and use | |
| CN114767778A (en) | Application of hosta plantaginea flower extract in preparation of medicine and health-care food for treating acute pharyngitis | |
| CN109350670A (en) | The preparation method of Ynxingchao dropping pills compound | |
| KR102358713B1 (en) | Compositions containing Acanthopanax sessiliflorum, Fagopyri Semen and Chaenomelis Fructus extracts for the Improvement of Allergic Rhinitis and Manufacturing Method Thereof | |
| CN114886914A (en) | Composition for relieving oral ulcer and preparation method and application thereof | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| CN114601891B (en) | Composition with anti-ulcerative colitis effect and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN102755519A (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN103860853A (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN101862392B (en) | New pharmaceutical application of cordate houttuynia in thrombus prevention | |
| CN101129436B (en) | Method of producing dandelion medicinal granules | |
| CN108143944A (en) | A kind of Chinese medicine composition for treating cold | |
| CN1907329A (en) | Children's rheum tablet and its preparation | |
| CN103610884B (en) | A kind of preparation method of composite reineckia carnea oral preparation | |
| CN115919918A (en) | Application of alcohol precipitation extract of towel gourd | |
| CN116763844A (en) | Traditional Chinese medicine composition for treating airway inflammation and preparation method thereof | |
| CN117717572A (en) | Herba Lycopodii or its extract, its composition and application | |
| CN112546152A (en) | A Chinese medicinal composition for treating oral and throat diseases, and its spray preparation method | |
| CN114344368A (en) | Application of nauclea officinalis extract in preparation of medicine for preventing and treating oral ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |